The short answer
Melatonin may add to carbinoxamine-related sleepiness or impairment. Review the dose and formulation, particularly if you already feel drowsy; the exact combination’s risk has not been quantified.
What this answer covers
Oral carbinoxamine with the specific preparation described below.
- Supplement or preparation
- Melatonin
- Medication ingredient
- carbinoxamine
Sleepiness is possible with both products
Carbinoxamine can impair alertness. Melatonin can also cause sleepiness, and its effects may last longer in some older people. That supports checking the combination against the actual dose and daily activities.
Feeling sleepy and measured performance are different
A small placebo-controlled study of afternoon melatonin found increased subjective sleepiness after a prolonged task, but no overall adverse effect on its objective driving-test battery. This does not mean every melatonin dose causes measurable impairment.
No exact combination estimate was established
The driving experiment did not include carbinoxamine. It cannot provide a combined event rate, prove increased medicine concentrations or validate a short dosing gap. Other medicines, alcohol and sleep deprivation can also affect the practical assessment.
Review the whole alertness burden
Bring the exact supplement label and all medicines to your pharmacist, particularly if carbinoxamine already makes you sleepy, dizzy or confused. Avoid driving when affected. The reviewed evidence does not identify a supplement dose or hours-apart schedule that guarantees normal alertness.
Evidence and practical considerations
Side effects & toxicity
Melatonin may add to carbinoxamine-related sleepiness or impairment. Review the dose and formulation, particularly if you already feel drowsy; the exact combination’s risk has not been quantified.
- Exact scope
- Oral carbinoxamine with the specific preparation described below. with Oral carbinoxamine; the hyoscine source, where relevant, is explicitly transdermal.
- Medication form and route
- oral
What remains uncertain
- Conditional alertness precaution from exact medication and melatonin effects. Original melatonin objective-performance null retained; no exact co-use incidence, PK change or respiratory-depression estimate.
Factors that may matter: Exact preparation and amount; Other medicines with overlapping effects; Route and gut-transit status where relevant.
Read the supporting source summaries
Source 1: Current U.S. regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral carbinoxamine.
Carbinoxamine is a sedating antihistamine with anticholinergic activity. The immediate-release label cautions about sedatives and tranquilizers; MAO inhibitors are separately contraindicated.
How this applies: Exact active ingredient and oral-route context.
Label warnings do not measure every exact supplement pair or provide a universal safe supplement dose or interval.
Source 2: Current U.S. regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed extended-release carbinoxamine maleate.
Warns of marked drowsiness and additional CNS depressant effects; anticholinergic effects matter in gastrointestinal obstruction.
How this applies: Additional exact-ingredient formulation context.
Extended-release exposure is not an immediate-release schedule. No exact botanical event rate.
Source 3: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the named botanical or supplement.
Sleepiness is a possible effect. Older people may have prolonged daytime drowsiness; commercial products and long-term safety data vary.
How this applies: Supports conditional alertness review without claiming every dose objectively impairs performance.
General guidance does not quantify this exact medication combination or establish a universal protective interval.
Source 4: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Twenty healthy adults in a crossover.
Subjective sleepiness increased after a prolonged task, but the overall objective driving-test battery did not show impairment.
How this applies: Supports nuance between sleepiness and measured performance.
Small, single-dose study, no meclizine, carbinoxamine or promethazine co-use.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial source-checked research draft with exact preparation limits, contrary findings and source-access details. Clinical review not recorded. | |
| Research summary published |
Article revision: 4a22bb616b06ba68
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.